San Diego, CA and Rehovot, Israel – June 2, 2017 – Sevion Therapeutics, Inc., (OTCQB: SVON) and Eloxx Pharmaceuticals Ltd., a clinical stage company developing therapeutics for genetic diseases caused by non-sense mutations, announced today the signing of a definitive  agreement on May 31, 2017 for an acquisition transaction. Under the terms of the agreement, Eloxx will become a […]

SAN DIEGO, CA – October 21, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCBB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, will give an invited oral presentation entitled “Engineering Cow Antibodies […]

Sevion Therapeutics Presents Antibody Discovery Platform at International Conference  SAN DIEGO, CA – September 22, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCBB: SVON), a biopharmaceutical company which discovers, develops, and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, M.D., Ph.D., Chief Scientific Officer, will […]

Sevion Therapeutics Announces Establishment of a Biophysical Characterization Applications Lab  SAN DIEGO, CA – July 30, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”) (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, has entered into an agreement with Malvern Instruments establishing a […]

SAN DIEGO, CA – May 4, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCBB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, gave an oral presentation on the company’s cow-derived ultralong CDR3 […]

SAN DIEGO, CA – December 8, 2014 – Sevion Therapeutics (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced the presentation of results from the Company’s Phase 1b/2a clinical trial of SNS01-T for the treatment of multiple myeloma and lymphoma. The results […]

Sevion Earnings Release – View as PDF » Bridgewater, NJ – November 17, 2014 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”) (OTCQB: SVON),  a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended September 30, 2014 (“First […]

BRIDGEWATER, N.J. (October 3rd, 2014) – Sevion Therapeutics (OTCQB: SVON), a clinical stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today that, on October 3, 2014, the Company’s common stock ceased trading under the ticker symbol “SNTI” and commenced trading under the ticker symbol “SVON.” […]

BRIDGEWATER, N.J. (September 9th, 2014) – Senesco Technologies, Inc. (OTCQB: SNTI) (the “Company” or “Sevion”), a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today a corporate rebranding under which the Company will change its name to Sevion Therapeutics, Inc. The Company will continue to […]